November 14th 2024
Transposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.
November 11th 2024
The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.
E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.
October 23rd 2024
Routine screening revealed high financial toxicity and unmet social needs among adolescent and young adults with cancer.
October 11th 2024
MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.
October 8th 2024
The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.
October 6th 2024
Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.
October 2nd 2024
The BCMA-targeting ADC HDP-101 demonstrated early efficacy and manageable toxicity in relapsed/refractory multiple myeloma.
September 27th 2024
Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
Combining talquetamab with teclistamab demonstrated responses even among those with extramedullary disease in the RedirecTT-1 trial.
September 26th 2024
Belantamab mafodotin-based combination appears to improve responses over time in those with transplant-eligible newly diagnosed multiple myeloma
September 24th 2024
Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.
September 16th 2024
In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.
Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.
September 13th 2024
Consistent survival benefit was seen with consolidation durvalumab across subgroups in the ADRIATIC trial affirms its use as a standard of care in LS-SCLC.
Adjuvant durvalumab did not provide a disease-free survival advantage over placebo in patients with NSCLC across different PD-L1 subgroups.
September 11th 2024
Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.
September 9th 2024
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.